Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

³úÇϼöü Á¦°Å ÈòÁã¿¡¼­ º¸»ó¼º½Åºñ´ë°úÁ¤ Áß ¿ÜÀμº IGF-¥°Åõ¿©°¡ ³»Àμº IGF-¥°ÀÇ »ý»ê, ½Å±â´É ¹× ½Åºñ´ëÀÇ ¼º°Ý¿¡ ¹ÌÄ¡´Â ¿µÇâ Effects of Exogenous IGF-¥° on Endogenous IGF-¥° Production, Function and Hyperplasia / Hypertrophy of Kidney during Compensatory Renal Growth in Hypophysectomized Rats

´ëÇѺñ´¢±â°úÇÐȸÁö 1999³â 40±Ç 6È£ p.749 ~ 755
ÇÑ»ó¿ø, Á¶Ã¶±Ô, ¹Îº´¼®,
¼Ò¼Ó »ó¼¼Á¤º¸
ÇÑ»ó¿ø (  ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

Á¶Ã¶±Ô (  ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç
¹Îº´¼® (  ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

Abstract

¼­·Ð
½ÅÀåÀÇ »ó´ç ºÎºÐÀÌ ¼Õ½ÇµÇ°Å³ª ±â´ÉÀÌ °¨¼ÒµÇ¾úÀ» ¶§ ³ª¸ÓÁö ½ÅÀå Á¶Á÷ ȤÀº »ó´ëÀûÀ¸·Î
±â´ÉÀÌ ÁÁÀº ºÎºÐ¿¡¼­´Â ºÎÁ·ÇÑ ½ÅÀå ±â´ÉÀ» ´ë½ÅÇϱâ À§ÇÏ¿© Á¶Á÷ÀÇ ±â´ÉÀÌ ±Ø´ëÈ­µÈ´Ù.
ÀÏ¸í º¸»ó¼º½Åºñ´ë¶ó°í ÇÏ´Â ÀÌ °úÁ¤ÀÇ ±â´ÉÀûÀΠƯ¡Àº ½ÅÇ÷·ù¿Í »ç±¸Ã¼ ¿©°úÀ²ÀÇ Áõ°¡ÀÌ
´Ù. ±×·¯³ª ½ÅÇ÷·ùÀÇ Áõ°¡´Â ¹Ù·Î »ç±¸Ã¼³»¾ÐÀÇ Áõ°¡·Î À̾îÁ® °á±¹ »ç±¸Ã¼ÀÇ °ú¿©°ú
(hyperfiltration)°¡ ÀϾ¸ç, »ç±¸Ã¼ÀÇ °ú¿©°ú´Â »ç±¸Ã¼°æÈ­(glomerulosclerosis)¸¦ ÀÏÀ¸ÄÑ
Àå±âÀûÀ¸·Î´Â ½ÅºÎÀü¿¡ À̸£°Ô µÈ´Ù. ±×·¸´Ù°í ÇÏ¿© »ç±¸Ã¼°æÈ­¸¦ ¹æÁö À§ÇÏ¿© ´Ü¹éÁúÀÇ °á
ÇÌÀ» À¯µµÇÏ¸é ½ÅÀå ±â´ÉÀÌ º¸»óµÇÁö ¾Ê¾Æ ½Å±â´ÉÀ» À¯ÁöÇÒ ¼ö ¾ø°Ô µÈ´Ù. À§¿Í °°ÀÌ º¸»ó
¼º½Åºñ´ë¿Í »ç±¸Ã¼°æÈ­´Â µ¿ÀüÀÇ ¾ÕµÞ¸é°ú °°´Ù. Á¤»óÀûÀÎ »ý¸®Àû Çö»ó ¼Ó¿¡¼­ »ç±¸Ã¼°æÈ­
°¡ ¾øÀÌ ½ÅÀå ±â´ÉÀÇ º¸»óÀÌ ³ªÅ¸³ªµµ·Ï ÇÏ´Â ¹°ÁúÀ» ¾ò±â À§ÇÑ ¸¹Àº ¿¬±¸°¡ Áö¼ÓµÇ¾î ¿ÔÀ¸
¸ç, insulin-like growth factor-¥°(IGF-¥°)Àº ÀÌ·¯ÇÑ ¹®Á¦µé ÁßÇϳªÀÌ´Ù. growth
hormone(GH)Àº ÇöÀç±îÁö ¾Ë·ÁÁø ½Å±â´É Ç×ÁøÁ¦ Áß¿¡¼­ °¡Àå °­·ÂÇÏ°Ô ½Å±â´ÉÀ» Ç×Áø½ÃÅ°
´Â È¿°ú¸¦ °¡Áö°í ÀÖÀ¸¸ç GHÀÇ ½ÅÀå¿¡ ´ëÇÑ ±â´É Ç×Áø ÀÛ¿ëÀº GHÀÇ Á÷Á¢ÀûÀÎ È¿°úº¸´Ùµµ
IGF-¥°ÀÇ Áõ°¡¸¦ ÅëÇÑ °£Á¢Àû È¿°ú°¡ ´õ Å« °ÍÀ¸·Î Áõ¸íµÇ¾ú´Ù. À̸¦ 'GH-IGF-¥° axis'¶ó
°í Çϸç, ÀÌ GH-IGF-¥° axisÀÇ ÀÛ¿ëÀº »ç±¸Ã¼ ¿©°úÀ²°ú ½ÅÇ÷·ù·® »Ó¸¸ ¾Æ´Ï¶ó ±ÙÀ§¼¼°ü
(proximal tubule)ÀÇ ÀçÈí¼ö±îÁö Áõ°¡½ÃŲ´Ù. ÇÏÁö¸¸ ÀÌ·¯ÇÑ GH-IGF-¥° axis´Â ½Å±â´ÉÀÇ
Ç×Áø°ú µ¿½Ã¿¡ »ç±¸Ã¼°æÈ­·Ð ÀÏÀ¸Å²´Ù´Â °ÍÀÌ ¹®Á¦ÀÌ´Ù. ±×·¯³ª ÇÑÆíÀ¸·Î´Â ±â°üÀÇ ±â´ÉÀÌ
³ª Å©±âÀÇ Áõ°¡°¡ ¾øÀ̵µ ÀÚ¿¬ÀûÀ¸·Î »ç±¸Ã¼°æÈ­¸¸ÀÌ ÀϾ´Â ¸¶¿ì½º°¡ ÀÖ°í, ÀÌ ¸¶¿ì½º´Â
ÀϹÝÀûÀÎ ¸¶¿ì½º¿Í´Â ´Ù¸¥ GH-IGF-¥° axis¸¦ °¡Áö°í ÀÖ´Ù´Â º¸°í´Â ±â°üÀÇ ¼ºÀåÀ» À¯µµÇÏ
´Â ±âÀü°ú »ç±¸Ã¼°æÈ­¸¦ ÀÏÀ¸Å°´Â ±âÀüÀÌ ¼­·Î ´Ù¸£´Ù´Â °ÍÀ» ½Ã»çÇÑ´Ù. ÀÌ µÎ ±âÀüÀÌ ´Ù¸£
°Ô ³ªÅ¸³ª´Â ÀÌÀ¯·Î IGF-¥°Àº 'GHÀÇÁ¸¼º IGF-¥°'°ú 'GH ºñÀÇÁ¸¼º IGF-¥°'À¸·Î ±¸º°µÇ¸ç
À̵éÀÌ °¢ °úÁ¤¿¡ °¢±â µ¶¸³ÀûÀ¸·Î ÀÛ¿ëÇϱ⠶§¹®ÀÎ °ÍÀ¸·Î »ý°¢µÇ¸ç, º» ¿¬±¸ÀÚ ¿ª½Ã º¸»ó
¼º½Åºñ´ë°úÁ¤ Áß¿¡ GH ºñÀÇÁ¸¼º IGF-¥°ÀÌ ½ÅÀåÀÇ ÁÖ·Î À©À§°ö½½¼¼°ü(distal convoluted
tubule)°ú ÁýÇÕ°ü(collecting duct)¿¡¼­ »ý»êµÇ´Â °ÍÀ» °üÂûÇÑ ¹Ù ÀÖ´Ù.
µû¶ó¼­ ÀúÀÚµéÀº ½ÅÀå ±â´ÉÀÌ ³ªºüÁú »óȲ¿¡¼­ ¿ÜºÎ¿¡¼­ IGF-¥°À» Åõ¿©ÇÏ¸é ½ÅÀå±â´ÉÀÇ
Ç×ÁøÀ» µµ¸ðÇϸ鼭µµ »ç±¸Ã¼°æÈ­´Â ³ªÅ¸³ªÁö ¾ÊÀ» ¼ö ÀÖÀ» °ÍÀ̶ó´Â °¡¼³ÇÏ¿¡ GH-IGF-¥°
axisÀÇ È¿°ú¸¦ ¹èÁ¦Çϱâ À§ÇÏ¿© ÈòÁã¿¡¼­ ³úÇϼöü¸¦ Á¦°ÅÇÑ ÈÄ ¾çÃø ½ÅÀåÀ» ¸ðµÎ ³²°Ü³õÀº
¾çÃø½Å ¸ðµ¨°ú ÇÑÂÊ ½ÅÀåÀ» Á¦°ÅÇÑ ´ÜÀϽŠ¸ðµ¨¿¡ recombinant human IGF-¥°(rhIGF-¥°)À»
Åõ¿©ÇÏ¿© ½ÅÀå±â´É º¯È­¸¦ °üÂûÇÏ°íÀÚ ÇÏ¿´´Ù.

Purpose: Compensatory renal hypertrophy(CRH) after loss of considerable renal volume
is essential process for recovery and maintenance of renal function, but on the other
hand CRH induces glomerulosclerosis, eventually renal failure. Recently, the considerable
studies reveal that insulin-like growth factor-¥°(IGF-¥°) is an important molecule
relating to renal hypertrophy. This study investigates the possibility of IGF-¥° as a
therapeutic agent, it should be proved whether External IGF-¥° affects renal function
and glomerulosclerosis or does not affect in devoid state of growth hormone(GH) effect.
Materials and Methods: 100-150g Sprague-Dawley male rats were hypophysectomized
by transpharyngeal approach and hypophysectomy were confirmed by daily monitoring
of body weight for 3 weeks. The left kidney were removed in the rats of UNX group
(uninephrectomy) and UNX+IGF-¥° group(IGF-¥° treated after uninephrectomy), and
sham operation were done in the other rats of control group and IGF-¥° group(IGF-¥°
treated). Recombinant IGF-¥° were administered via Alzet osmotic minipump for 5 days
in rats of IGF-¥° group and UNX+IGF-¥° group. At the 5th day after uninephrectomy,
the glomerular filtration rate(GFR) and the effective renal plasma flow(ERPF) were
investigated by measuring recovery of 99mTc-DTPA and
125I-hippurate, and then the rats were sacrificed and the kidneys were
removed. The wet kidney weights were measured in removed kidneys, renal IGF-¥°
concentrations were measured by RIA, andcellularproliferationwereevaluated by
flow-cytometry.
Results: 1. The wet kidney weight per body weight significantly increased after
uninephrectomy, and had not been affected by IGF-¥° treatment regardless of
uninephrectomy. 2. Renal IGF-¥° tended to increase after uninephrectomy, and
significantly increased with IGF-¥° treatment in both IGF-¥° and UNX+IGF-¥°. The
level of renal IGF-¥° of UNX+IGF-¥° group was significantly higher than that of IGF-
¥° group. 3. Total GFR tended to decreased after uninephrectomy and were significantly
increased by IGF-¥° treatment regardless of uninephrectomy. 4. The GFR per g wet
kidney weight significantly increased after uninephrectomy, and were significantly
increased by IGF-¥° treatment regardless of uninephrectomy. 5. Total ERPF were not
significantly changed after uninephrectomy and significantly increased by IGF-¥°
treatment in sham operation group but did not changed by IGF-¥° treatment in
uninephrectomy group. 6. The ERPF per g wet weight significantly increased after
uninephrectomy, and significantly increased by IGF-¥° treatment in sham operation
group but did not changed by IGF-¥° treatment In uninephrectomy group. 7. The mean
% of S1 phase cells were 33.6% in UNX+IGF-¥° group, 23.5% in IGF-¥° group, 19.96%
in UNX group, and 10.4% in control group. The mean % of G2+M phase cells were
2.5% in UNX+IGF-¥° group, l.95% in IGF-¥° group, 1.73% in UNX group, and 1.2% in
control group.
Conclusions: GH non-dependent IGF-¥° participate in CRH, and only IGF-¥° without
GH increases renal function. IGF-¥° treatment during CRH might increase GFR by
changing glomerular efferent arteriol of filtration fraction.

Å°¿öµå

Insulin-like growth factor-1; Growth hormone; Hypophysectomy; Kidney;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS